Merck Secures EU Nod for RSV Antibody Enflonsia in Infants [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
respiratory tract disease in newborns and infants during their first RSV season. Enflonsia is contraindicated for infants with hypersensitivity to the active substance or any of its other components. Following the latest nod, Enflonsia became the first and only RSV preventive option for administration to infants without the need for weight-based dosing in the European Union ("EU"). The nod in the EU was based on data from the pivotal phase IIb/III CLEVER study, which evaluated the safety and efficacy of a single dose of Enflonsia administered to preterm and full-term infants, as well as interim data from RSV season 1 of the Phase 3 SMART study, evaluating the safety, efficacy and pharmacokinetics of Enflonsia versus palivizumab in infants who stand at increased risk for severe RSV disease. Merck's Stock Performance Year to date, shares of Merck have rallied 13.1% against the industry's decline of 2.8%. Zacks Investment Research Image Source: Zacks Investment Research L
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- What To Expect From Sanofi In Q1 2026 [Seeking Alpha]Seeking Alpha
- Sanofi (SNY) was downgraded by BNP Paribas Exane from "outperform" to "neutral".MarketBeat
- Is Sanofi (SNY) One of the Best Affordable Blue Chip Stocks to Buy Now? [Yahoo! Finance]Yahoo! Finance
- Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study [Yahoo! Finance]Yahoo! Finance
- Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyGlobeNewswire
SNY
Sec Filings
- 4/15/26 - Form 6-K
- 4/10/26 - Form SCHEDULE
- 3/31/26 - Form 6-K
- SNY's page on the SEC website